Pulmonx (DE:4NI)
FRANKFURT:4NI
Earnings Data
Report Date
Aug 05, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.24Last Year’s EPS
-0.33Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call mixes clear near-term challenges (Q1 revenue declines, China registration-driven international disruption, ongoing net losses) with several meaningful positive developments: improved gross margin, cost reductions lowering operating expense trajectory, strengthened liquidity via a $60M credit facility, addition of U.S. treating centers and filled sales roles, and progressing pivotal clinical enrollment that could expand TAM by ~20%. Management reiterated full-year guidance of $90M–$92M and expects sequential improvement with a return to growth in H2 2026. The narrative is execution- and timing-dependent but supported by concrete operational and financial actions that materially reduce downside risk.Company Guidance
Reiterated Full-Year Revenue Guidance and Return-to-Growth Plan
Reiterated 2026 revenue guidance of $90M–$92M and expects sequential quarter-on-quarter improvement with return to year-over-year growth in both U.S. and international businesses in the back half of 2026 and exit the year with double-digit growth.
First Quarter Revenue and Commercial Progress
Total worldwide revenue of $20.6M in Q1 2026; U.S. revenue $13.3M. Added 15 new U.S. treating centers in Q1 and substantially filled U.S. sales leadership and field roles, with sales turnover stabilized over the last 6 months.
Gross Margin Expansion
Gross margin improved to 78% in Q1 2026 from 73% a year ago, driven primarily by a lower mix of distributor sales; company expects full-year gross margin of approximately 75% (higher in H1, lower in H2 based on mix).
Cost Reduction and Improved Operating Expense Trajectory
Executed a broad cost reduction initiative reducing ongoing operating expenses by over 10%; total operating expenses were $29M (down 6% YoY) and, excluding stock-based compensation and one-time restructuring, operating expenses decreased 8% YoY. Full-year operating expense guidance $113M–$115M (includes ~$19M stock-based comp).
Adjusted EBITDA and Loss Improvement
Reported adjusted EBITDA loss of $8.5M in Q1 (consistent with prior year); excluding one-time restructuring charges, adjusted EBITDA loss was $7.0M, an 18% improvement versus prior year. Net loss narrowed to $13.7M (−$0.33 per share) from $14.4M (−$0.36).
Strengthened Liquidity and Extended Runway
Ended Q1 with $61.6M in cash, cash equivalents and marketable securities. Closed a $60M credit facility (5-year interest-only) extending debt maturity to 2031 and access to an additional $20M subject to revenue milestones. Expect full-year 2026 cash burn of ~ $23M vs $32M in 2025.
Clinical Progress and TAM Expansion Opportunity
CONVERT II pivotal trial for AeriSeal is progressing well with improved enrollment pace after clinical leadership changes; company is highly confident of completing enrollment in 2027. AeriSeal could expand total addressable market by ~20% globally and serve as a medium- to long-term revenue driver.
DE:4NI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:4NI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | €1.04 | €1.03 | -0.96% |
Mar 04, 2026 | €1.25 | €1.17 | -6.40% |
Nov 12, 2025 | €1.75 | €1.66 | -5.14% |
Jul 30, 2025 | €2.62 | €2.18 | -16.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pulmonx (DE:4NI) report earnings?
Pulmonx (DE:4NI) is schdueled to report earning on Aug 05, 2026, After Close (Confirmed).
What is Pulmonx (DE:4NI) earnings time?
Pulmonx (DE:4NI) earnings time is at Aug 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Pulmonx stock?
The P/E ratio of Pulmonx is N/A.
What is DE:4NI EPS forecast?
DE:4NI EPS forecast for the fiscal quarter 2026 (Q2) is -0.24.